Kim Ee Hyun, Jeon Seungho, Park Junyoung, Ryu Ji Hyun, Mobasheri Ali, Matta Csaba, Jin Eun-Jung
Integrated Omics Institute, Wonkwang University, Iksan, Republic of Korea.
Department of Biomedical Materials Science, Graduate School of JABA, Wonkwang University, Iksan, Republic of Korea.
Exp Mol Med. 2025 Jun;57(6):1133-1142. doi: 10.1038/s12276-025-01481-6. Epub 2025 Jun 30.
Osteoarthritis (OA) is marked by cartilage degradation, inflammation and varied pain. Traditional treatments such as nonsteroidal anti-inflammatory drugs primarily offer symptom relief without halting disease progression. Advances in regenerative medicine and stem cell and gene therapies, combined with innovative biomaterials such as hydrogels, present new opportunities to target the underlying pathophysiology of OA. This review explores these promising approaches alongside the emerging roles of circadian biology and organelle health in OA pathogenesis and therapy. It highlights the shift toward precision medicine, offering a comprehensive analysis of emerging targeted strategies aimed at improving OA management and patient outcomes.
骨关节炎（OA）的特征是软骨退化、炎症和不同程度的疼痛。传统治疗方法如非甾体抗炎药主要是缓解症状，而无法阻止疾病进展。再生医学、干细胞和基因疗法的进展，以及水凝胶等创新生物材料的出现，为针对OA的潜在病理生理学提供了新的机会。本文综述探讨了这些有前景的方法，以及昼夜节律生物学和细胞器健康在OA发病机制和治疗中的新作用。它强调了向精准医学的转变，全面分析了旨在改善OA管理和患者预后的新兴靶向策略。
